Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,387

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Unravelling mechanisms of p53-mediated tumour suppression

Open access
Bieging, Kathryn T., Mello, Stephano Spano, Attardi, Laura D.·2014·Nature Reviews Cancer
DOI 10.1038/nrc3711
Open this paper in CoChat — free account

Abstract

p53 is a crucial tumour suppressor that responds to diverse stress signals by orchestrating specific cellular responses, including transient cell cycle arrest, cellular senescence and apoptosis, which are all processes associated with tumour suppression. However, recent studies have challenged the relative importance of these canonical cellular responses for p53-mediated tumour suppression and have highlighted roles for p53 in modulating other cellular processes, including metabolism, stem cell maintenance, invasion and metastasis, as well as communication within the tumour microenvironment. In this Opinion article, we discuss the roles of classical p53 functions, as well as emerging p53-regulated processes, in tumour suppression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc3711

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 133

  1. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861–872 (2004). · DOI · Paper page
  2. Song, H. Hollstein, M. & Xu, Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nature Cell Biol. 9, 573–580 (2007). · DOI · Paper page
  3. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990). · DOI · Paper page
  4. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990). · DOI · Paper page
  5. Miller, L. D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA 102, 13550–13555 (2005). · DOI · Paper page
  6. Olivier, M. & Taniere, P. Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Curr. Opin. Oncol. 23, 88–92 (2011). · DOI
  7. Mizuno, H., Spike, B. T., Wahl, G. M. & Levine, A. J. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc. Natl Acad. Sci. USA 107, 22745–22750 (2010). · DOI · Paper page
  8. Rivlin, N., Brosh, R., Oren, M. & Rotter, V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2, 466–474 (2011). · DOI · Paper page
  9. Giaccia, A. J. & Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973–2983 (1998). · DOI · Paper page
  10. Hu, W., Feng, Z. & Levine, A. J. The regulation of multiple p53 stress responses is mediated through MDM2. Genes Cancer 3, 199–208 (2012). · DOI
  11. Brady, C. A. et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571–583 (2011). · DOI · Paper page
  12. Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269–1283 (2012). · DOI · Paper page
  13. Valente, L. J. et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 3, 1339–1345 (2013). · DOI · Paper page
  14. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1–7 (1994). · DOI · Paper page
  15. Purdie, C. A. et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9, 603–609 (1994).
  16. Harvey, M. et al. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7, 938–943 (1993). · DOI · Paper page
  17. Attardi, L. D. & Donehower, L. A. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat. Res. 576, 4–21 (2005). · DOI
  18. Friedman, P. N., Chen, X., Bargonetti, J. & Prives, C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl Acad. Sci. USA 90, 3319–3323 (1993). · DOI · Paper page
  19. Smeenk, L. et al. Role of p53 serine 46 in p53 target gene regulation. PLoS ONE 6, e17574 (2011). · DOI · Paper page
  20. Kenzelmann Broz, D. et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev. 27, 1016–1031 (2013). · DOI · Paper page
  21. Nikulenkov, F. et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ. 19, 1992–2002 (2012). · DOI · Paper page
  22. Johnson, T. M., Hammond, E. M., Giaccia, A. & Attardi, L. D. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nature Genet. 37, 145–152 (2005). · DOI
  23. Jiang, D. et al. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc. Natl Acad. Sci. USA 108, 17123–17128 (2011). · DOI
  24. el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993). · DOI · Paper page
  25. Martin-Caballero, J., Flores, J. M., Garcia-Palencia, P. & Serrano, M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 61, 6234–6238 (2001).
  26. Hollander, M. C. et al. Genomic instability in Gadd45a-deficient mice. Nature Genet. 23, 176–184 (1999). · DOI · Paper page
  27. Doumont, G. et al. G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv. EMBO J. 24, 3093–3103 (2005). · DOI
  28. Wang, Z. G. et al. Role of PML in cell growth and the retinoic acid pathway. Science 279, 1547–1551 (1998). · DOI · Paper page
  29. Rego, E. M. et al. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 193, 521–529 (2001). · DOI
  30. Tront, J. S., Hoffman, B. & Liebermann, D. A. Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res. 66, 8448–8454 (2006). · DOI
  31. Tront, J. S. et al. Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress. Cancer Res. 70, 9671–9681 (2010). · DOI
  32. Hildesheim, J. et al. Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res. 62, 7305–7315 (2002).
  33. Ludwig, R. L., Bates, S. & Vousden, K. H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16, 4952–4960 (1996). · DOI · Paper page
  34. Rowan, S. et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 15, 827–838 (1996). · DOI · Paper page
  35. Brosh, R. & Rotter, V. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Mol. Biosyst. 6, 17–29 (2010). · DOI
  36. Barboza, J. A., Liu, G., Ju, Z., El-Naggar, A. K. & Lozano, G. p21 delays tumor onset by preservation of chromosomal stability. Proc. Natl Acad. Sci. USA 103, 19842–19847 (2006). · DOI
  37. Timofeev, O. et al. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep. 3, 1512–1525 (2013). · DOI
  38. Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071–1078 (2009). · DOI · Paper page
  39. Tron, V. A., Trotter, M. J., Ishikawa, T., Ho, V. C. & Li, G. p53-dependent regulation of nucleotide excision repair in murine epidermis in vivo. J. Cutan. Med. Surg. 3, 16–20 (1998). · DOI
  40. Tang, W., Willers, H. & Powell, S. N. p53 directly enhances rejoining of DNA double-strand breaks with cohesive ends in gamma-irradiated mouse fibroblasts. Cancer Res. 59, 2562–2565 (1999).
  41. Seo, Y. R., Fishel, M. L., Amundson, S., Kelley, M. R. & Smith, M. L. Implication of p53 in base excision DNA repair: in vivo evidence. Oncogene 21, 731–737 (2002). · DOI
  42. Hollander, M. C. et al. Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc. Natl Acad. Sci. USA 102, 13200–13205 (2005). · DOI
  43. Melis, J. P. et al. Mouse models for xeroderma pigmentosum group A and group C show divergent cancer phenotypes. Cancer Res. 68, 1347–1353 (2008). · DOI
  44. Friedberg, E. C. et al. Defective nucleotide excision repair in xpc mutant mice and its association with cancer predisposition. Mutat. Res. 459, 99–108 (2000). · DOI
  45. Dankort, D. et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379–384 (2007). · DOI · Paper page
  46. Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010). · DOI · Paper page
  47. Yin, C., Knudson, C. M., Korsmeyer, S. J. & Van Dyke, T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637–640 (1997). · DOI · Paper page
  48. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670–2677 (1999). · DOI · Paper page
  49. Schmitt, C. A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289–298 (2002). · DOI · Paper page
  50. Jeffers, J. R. et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321–328 (2003). · DOI · Paper page
  51. Knudson, C. M., Johnson, G. M., Lin, Y. & Korsmeyer, S. J. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res. 61, 659–665 (2001).
  52. Ihrie, R. A., Bronson, R. T. & Attardi, L. D. Adult mice lacking the p53/p63 target gene Perp are not predisposed to spontaneous tumorigenesis but display features of ectodermal dysplasia syndromes. Cell Death Differ. 13, 1614–1618 (2006). · DOI
  53. Eischen, C. M., Roussel, M. F., Korsmeyer, S. J. & Cleveland, J. L. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 21, 7653–7662 (2001). · DOI · Paper page
  54. Michalak, E. M. et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 16, 684–696 (2009). · DOI · Paper page
  55. Dansen, T. B., Whitfield, J., Rostker, F., Brown-Swigart, L. & Evan, G. I. Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo. J. Biol. Chem. 281, 10890–10895 (2006). · DOI
  56. Hemann, M. T. et al. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl Acad. Sci. USA 101, 9333–9338 (2004). · DOI · Paper page
  57. Beaudry, V. G. et al. Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet. 6, e1001168 (2010). · DOI
  58. Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355 (2008). · DOI · Paper page
  59. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864–870 (2005). · DOI · Paper page
  60. Efeyan, A., Garcia-Cao, I., Herranz, D., Velasco-Miguel, S. & Serrano, M. Tumour biology: policing of oncogene activity by p53. Nature 443, 159 (2006). · DOI
  61. Hinkal, G., Parikh, N. & Donehower, L. A. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS ONE 4, e6654 (2009). · DOI
  62. Christophorou, M. A. et al. Temporal dissection of p53 function in vitro and in vivo. Nature Genet. 37, 718–726 (2005). · DOI · Paper page
  63. Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567–571 (2010). · DOI · Paper page
  64. Hammond, E. M. et al. Genome-wide analysis of p53 under hypoxic conditions. Mol. Cell. Biol. 26, 3492–3504 (2006). · DOI
  65. Sablina, A. A. et al. The antioxidant function of the p53 tumor suppressor. Nature Med. 11, 1306–1313 (2005). · DOI · Paper page
  66. Maddocks, O. D. & Vousden, K. H. Metabolic regulation by p53. J. Mol. Med. 89, 237–245 (2011). · DOI · Paper page
  67. Kawauchi, K. Araki, K., Tobiume, K. & Tanaka, N. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nature Cell Biol. 10, 611–618 (2008). · DOI · Paper page
  68. Schwartzenberg-Bar-Yoseph, F., Armoni, M. & Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 64, 2627–2633 (2004). · DOI · Paper page
  69. Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107–120 (2006). · DOI · Paper page
  70. Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V. & Chumakov, P. M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304, 596–600 (2004). · DOI · Paper page
  71. Hu, W. et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl Acad. Sci. USA 107, 7455–7460 (2010). · DOI · Paper page
  72. Budanov, A. V. Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid. Redox Signal 15, 1679–1690 (2011). · DOI · Paper page
  73. Gottlieb, E. & Vousden, K. H. p53 regulation of metabolic pathways. Cold Spring Harb. Perspect Biol. 2, a001040 (2010). · DOI · Paper page
  74. Yang, Z. & Klionsky, D. J. An overview of the molecular mechanism of autophagy. Curr. Top. Microbiol. Immunol. 335, 1–32 (2009).
  75. Mathew, R. & White, E. Autophagy, stress, and cancer metabolism: what doesn't kill you makes you stronger. Cold Spring Harb. Symp. Quant. Biol. 76, 389–396 (2011). · DOI
  76. Gao, W., Shen, Z., Shang, L. & Wang, X. Upregulation of human autophagy-initiation kinase ULK1 by tumor suppressor p53 contributes to DNA-damage-induced cell death. Cell Death Differ. 18, 1598–1607 (2011). · DOI · Paper page
  77. Long, J. S. et al. Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol. Cell 50, 394–406 (2013). · DOI
  78. Hanna, J. et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462, 595–601 (2009). · DOI · Paper page
  79. Li, H. et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136–1139 (2009). · DOI · Paper page
  80. Utikal, J. et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460, 1145–1148 (2009). · DOI · Paper page
  81. Sarig, R. et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J. Exp. Med. 207, 2127–2140 (2010). · DOI
  82. Yi, L., Lu, C., Hu, W., Sun, Y. & Levine, A. J. Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation. Cancer Res. 72, 5635–5645 (2012). · DOI
  83. Choi, Y. J. et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nature Cell Biol. 13, 1353–1360 (2011). · DOI · Paper page
  84. Zhao, Z. et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 24, 1389–1402 (2010). · DOI
  85. Lu, X. et al. Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol. Cell. Biol. 21, 6017–6030 (2001). · DOI
  86. Elyada, E. et al. CKIα ablation highlights a critical role for p53 in invasiveness control. Nature 470, 409–413 (2011). · DOI · Paper page
  87. Alexandrova, A., Ivanov, A., Chumakov, P., Kopnin, B. & Vasiliev, J. Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization. Oncogene 19, 5826–5830 (2000). · DOI
  88. Guo, F. Gao, Y., Wang, L. & Zheng, Y. p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities. J. Biol. Chem. 278, 14414–14419 (2003). · DOI
  89. Guo, F. & Zheng, Y. Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene 23, 5577–5585 (2004). · DOI
  90. Gadea, G., Lapasset, L., Gauthier-Rouviere, C. & Roux, P. Regulation of Cdc42-mediated morphological effects: a novel function for p53. EMBO J. 21, 2373–2382 (2002). · DOI
  91. Gadea, G., de Toledo, M., Anguille, C. & Roux, P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J. Cell Biol. 178, 23–30 (2007). · DOI · Paper page
  92. Kim, N. H. et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol. 195, 417–433 (2011). · DOI · Paper page
  93. Chang, C. J. et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biol. 13, 317–323 (2011). · DOI · Paper page
  94. Kim, T. et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 208, 875–883 (2011). · DOI · Paper page
  95. Jiang, Z. et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J. Clin. Invest. 120, 3296–3309 (2010). · DOI
  96. Schwitalla, S. et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 23, 93–106 (2013). · DOI · Paper page
  97. Bornachea, O. et al. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci. Rep. 2, 434 (2012). · DOI
  98. Dameron, K. M., Volpert, O. V., Tainsky, M. A. & Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582–1584 (1994). · DOI · Paper page
  99. Menendez, D., Shatz, M. & Resnick, M. A. Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 25, 85–92 (2013). · DOI
  100. Kurose, K. et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nature Genet. 32, 355–357 (2002). · DOI · Paper page
  101. Matsumoto, N., Yoshida, T., Yamashita, K., Numata, Y. & Okayasu, I. Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma. Br. J. Cancer 89, 707–712 (2003). · DOI
  102. Paterson, R. F. et al. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer 98, 1830–1836 (2003). · DOI
  103. Tuhkanen, H. et al. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int. J. Cancer 109, 247–252 (2004). · DOI
  104. Kiaris, H. et al. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res. 65, 1627–1630 (2005). · DOI · Paper page
  105. Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nature Rev. Cancer 2, 594–604 (2002). · DOI · Paper page
  106. Dittmer, D. et al. Gain of function mutations in p53. Nature Genet. 4, 42–46 (1993). · DOI · Paper page
  107. Liu, D. P., Song, H. & Xu, Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29, 949–956 (2010). · DOI · Paper page
  108. Hanel, W. et al. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 20, 898–909 (2013). · DOI · Paper page
  109. Heinlein, C. et al. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int. J. Cancer 122, 1701–1709 (2008). · DOI
  110. Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nature Cell Biol. 15, 2–8 (2013). · DOI · Paper page
  111. Liu, K., Ling, S. & Lin, W. C. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol. Cell. Biol. 31, 4464–4481 (2011). · DOI
  112. Strano, S. et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277, 18817–18826 (2002). · DOI · Paper page
  113. Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T. & Prives, C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21, 1874–1887 (2001). · DOI · Paper page
  114. Martynova, E. et al. Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget 3, 132–143 (2012). · DOI
  115. Meek, D. W. & Anderson, C. W. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb. Perspect Biol. 1, a000950 (2009).
  116. Chehab, N. H., Malikzay, A., Stavridi, E. S. & Halazonetis, T. D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl Acad. Sci. USA 96, 13777–13782 (1999). · DOI · Paper page
  117. Oliner, J. D. et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857–860 (1993). · DOI · Paper page
  118. Jenkins, L. M., Durell, S. R., Mazur, S. J. & Appella, E. p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis 33, 1441–1449 (2012). · DOI
  119. Bates, S. et al. p14ARF links the tumour suppressors RB and p53. Nature 395, 124–125 (1998). · DOI · Paper page
  120. DeGregori, J., Leone, G., Miron, A., Jakoi, L. & Nevins, J. R. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA 94, 7245–7250 (1997). · DOI · Paper page
  121. Zhang, Y. & Xiong, Y. Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ. 12, 175–186 (2001).
  122. Zhang, Y. & Xiong, Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3, 579–591 (1999). · DOI · Paper page
  123. Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J. & Bar-Sagi, D. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1, 20–26 (1999). · DOI · Paper page
  124. Hacke, K. et al. Regulation of MCP-1 chemokine transcription by p53. Mol. Cancer 9, 82 (2010). · DOI · Paper page
  125. Gorgoulis, V. G. et al. p53 activates ICAM-1 (CD54) expression in an NF-κB-independent manner. EMBO J. 22, 1567–1578 (2003). · DOI
  126. Italiano, D., Lena, A. M., Melino, G. & Candi, E. Identification of NCF2/p67phox as a novel p53 target gene. Cell Cycle 11, 4589–4596 (2012). · DOI
  127. Lefort, K. et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKα kinases. Genes Dev. 21, 562–577 (2007). · DOI · Paper page
  128. Feng, Z. & Levine, A. J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 20, 427–434 (2010). · DOI · Paper page
  129. Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I. & Vousden, K. H. Metabolic regulation by p53 family members. Cell. Metab. 18, 617–633 (2013). · DOI · Paper page
  130. Braastad, C. D., Leguia, M. & Hendrickson, E. A. Ku86 autoantigen related protein-1 transcription initiates from a CpG island and is induced by p53 through a nearby p53 response element. Nucleic Acids Res. 30, 1713–1724 (2002). · DOI
  131. Liang, Y., Liu, J. & Feng, Z. The regulation of cellular metabolism by tumor suppressor p53. Cell Biosci. 3, 9 (2013). · DOI
  132. Shiraishi, K. et al. Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res. 60, 3722–3726 (2000).
  133. Post, S. M. et al. p53-dependent senescence delays Eμ-myc-induced B-cell lymphomagenesis. Oncogene 29, 1260–1269 (2010). · DOI

Cited by

See all 1,387

Metadata

Authors
Bieging, K. T., Mello, S. S., & Attardi, L. D.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2014-04-17
Volume
14
Issue
5
Pages
359-370
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/nrc3711
OpenAlex
W1966841369
Cited by
1,387
References
53
FWCI
13.09
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unravelling mechanisms of p53-mediated tumour suppression. https://app.cochat.ai/papers/10.1038/nrc3711
The paper
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014). Unravelling mechanisms of p53-mediated tumour suppression. Nature Reviews Cancer. https://doi.org/10.1038/nrc3711

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.